Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Bagnasco (GENOVA (GE), Italy), A. Riccio (GENOVA (GE), Italy), L. De Ferrari (GENOVA (GE), Italy), M. Caminati (Verona, Italy), A. Massolo (Pisa, Italy), G. Senna (Verona, Italy), G. Passalacqua (GENOVA (GE), Italy). Serum YKL-40 modulation in severe asthma patients treated with Mepolizumab. 2230

Member's Comments

No comment yet.

Related content which might interest you: Serum levels of IL-6 in adult patients with moderate to severe asthma. Source: International Congress 2017 – Novel mechanisms in asthma Year: 2017 Serum interleukin-6 levels correlate with malnutrition in patients with acute exacerbation of COPD Source: Annual Congress 2009 - Organisation of care for individuals with chronic respiratory disease Year: 2009 Serum Amphiregulin expression in severe asthma patients treated with anti-IL-5 therapy Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Serum Interleukin (IL)-6 levels in patients with severe asthma disease is associated with blood eosinophilia Source: Virtual Congress 2020 – Clinical characteristics and diagnostic tools for phenotyping asthma and COPD Year: 2020 Monitoring free serum IgE in severe asthma patients treated with omalizumab Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Serum levels of interleukin-18 in patients affected by allergic bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 30s Year: 2002 Elevated serum inflammatory markers in patients with stable COPD Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease Year: 2009 Serum leptin levels in patients with chronic airway diseases Source: Eur Respir J 2005; 26: Suppl. 49, 306s Year: 2005 Serum neopterin and IL-6 as biomarkers in patients with COPD. Source: International Congress 2017 – Novel molecular and genetic targets in COPD Year: 2017 Serum magnesium levels in acute exacerbation of COPD Source: Annual Congress 2007 - Exacerbations of COPD Year: 2007 Oral corticosteroid treatment reduces serum chitotriosidase activity in patients with COPD Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 Increase in systemic IL-5 is associated with mepolizumab treatment failure in patients with severe asthma Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Activin-A levels in sputum and serum of COPD, asthma and ACOS patients during acute exacerbation and at baseline Source: International Congress 2017 – Infection and exacerbation science Year: 2017 Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD Source: International Congress 2017 – COPD biomarkers Year: 2017 Elevated serum IL-12 and IL-18 levels in patients with bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 424s Year: 2002 Monitoring free serum IgE in asthma patients treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Effect of systemic steroid treatment on serum leptin levels in patients with COPD exacerbation Source: Eur Respir J 2005; 26: Suppl. 49, 284s Year: 2005 Increased serum endotoxin levels as biomarker in acute exacerbations of COPD. Source: International Congress 2018 – Biomarkers of COPD Year: 2018 Serum eosinophil cationic protein as a potential biomarker for interleukin-5 antibody treatment in patients with severe uncontrolled eosinophilic asthma Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Serum level of soluble interleukin-2 receptors (sIL-2R) during acute asthma exacerbation, and its relation to severity and response to bronchodilator therapy Source: Eur Respir J 2002; 20: Suppl. 38, 141s Year: 2002